Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5452893 | 1.00 | NOTUM (0.31) | NOTUMKDR | |
| SCHEMBL5943222 | 0.84 | MEN1 (0.42) | — | |
| SCHEMBL5943224 | 0.84 | MEN1 (0.42) | — | |
| SCHEMBL5943225 | 0.84 | C1S (0.35) | — | |
| SCHEMBL5943229 | 0.84 | C1S (0.35) | — | |
| SCHEMBL5455411 | 0.83 | GSK3B (0.33) | — | |
| SCHEMBL5455414 | 0.83 | GSK3B (0.33) | — | |
| SCHEMBL5454744 | 0.81 | RAB9A (0.40) | KDR | |
| SCHEMBL5943250 | 0.78 | KCNK3 (0.35) | — | |
| SCHEMBL5943253 | 0.78 | KCNK3 (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070287721-A1 | Pyrazolopyridinyl pyridine | BOYD F LESLIE | 2007-12-13 | — | — | US | disclosed |
| US-7163940-B2 | Pyrazolopyridinyl pyrimidine therapeutic compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2007-01-16 | — | — | US | disclosed |
| US-20060293344-A1 | Therapeutic Compounds | BOYD F L | 2006-12-28 | — | — | US | disclosed |
| US-7153855-B2 | Pyrazolopyridinyl pyrimidine therapeutic compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2006-12-26 | — | — | US | disclosed |
| EP-1377573-B1 | PYRAZOLOPYRIDINE DERIVATIVES | GLAXO GROUP LTD (GB) | 2005-07-27 | — | — | EP | disclosed |
| US-20050049260-A1 | Therapeutic compounds | SMITHKLINE BEECHAM CORPORATION | 2005-03-03 | — | — | US | disclosed |
| US-20050049259-A1 | Theraopeutic compounds | SMITHKLINE BEECHAM CORPORATION | 2005-03-03 | — | — | US | disclosed |
| EP-1366048-B1 | PYRAZOLOPYRIDINE DERIVATIVES | SMITHKLINE BEECHAM CORP (US) | 2004-08-25 | — | — | EP | disclosed |
| EP-1377573-A2 | PYRAZOLOPYRIDINE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2004-01-07 | — | — | EP | disclosed |
| EP-1366048-A2 | PYRAZOLOPYRIDINE DERIVATIVES | SmithKline Beecham Corporation (US) | 2003-12-03 | — | — | EP | disclosed |
| WO-2002072581-A2 | PYRAZOLOPYRIADINE DERIVATIVES | SMITHKLINE BEECHAM CORPORATION (US) | 2002-09-19 | — | — | WO | disclosed |
| WO-2002048148-A2 | PYRAZOLOPYRIDINE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2002-06-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050049259-A1 | Theraopeutic compounds | PCSK9, FOLH1, EPHA2 | NOTUM 3418/4885KDR 456/4885 |
| US-20060293344-A1 | Therapeutic Compounds | PCSK9, ABCB1, ABCB11 | NOTUM 765/4885KDR 4085/4885 |
| US-20070287721-A1 | Pyrazolopyridinyl pyridine | CYP3A5, CYP2C19, CYP3A4 | NOTUM 1022/4885KDR 3259/4885 |
| US-20050049260-A1 | Therapeutic compounds | ABCB1, PCSK9, ABCB11 | NOTUM 762/4885KDR 4025/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.